Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Financing Activities (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Cash from Financing Activities for 5 consecutive years, with $7.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 257.52% year-over-year to $7.7 million, compared with a TTM value of $33.0 million through Dec 2025, up 169.22%, and an annual FY2025 reading of $33.0 million, up 169.22% over the prior year.
  • Cash from Financing Activities was $7.7 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $11.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $11.9 million in Q3 2025 and bottomed at -$178000.0 in Q2 2024.
  • Average Cash from Financing Activities over 5 years is $2.8 million, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities crashed 212.66% in 2024, then surged 6110.11% in 2025.
  • Year by year, Cash from Financing Activities stood at $1.2 million in 2021, then fell by 1.82% to $1.2 million in 2022, then crashed by 41.6% to $695000.0 in 2023, then surged by 208.2% to $2.1 million in 2024, then surged by 257.52% to $7.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for KNSA at $7.7 million in Q4 2025, $11.9 million in Q3 2025, and $10.7 million in Q2 2025.